Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery

IF 4.1 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Gynecologic oncology Pub Date : 2025-04-19 DOI:10.1016/j.ygyno.2025.04.519
Emmeline L. Friedman , X. Mona Guo , Katelyn B. Furey , Alice J. Lee , Shinya Matsuzaki , Mamoru Kakuda , Mariya Kobayashi , Michiko Kodama , Hiroyuki Kanao , Maximilian Klar , Lynda D. Roman , Jason D. Wright , Koji Matsuo
{"title":"Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery","authors":"Emmeline L. Friedman ,&nbsp;X. Mona Guo ,&nbsp;Katelyn B. Furey ,&nbsp;Alice J. Lee ,&nbsp;Shinya Matsuzaki ,&nbsp;Mamoru Kakuda ,&nbsp;Mariya Kobayashi ,&nbsp;Michiko Kodama ,&nbsp;Hiroyuki Kanao ,&nbsp;Maximilian Klar ,&nbsp;Lynda D. Roman ,&nbsp;Jason D. Wright ,&nbsp;Koji Matsuo","doi":"10.1016/j.ygyno.2025.04.519","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To assess temporal trends of sentinel lymph node biopsy alone without additional lymphadenectomy at surgery for cervical cancer in the United States.</div></div><div><h3>Methods</h3><div>This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Study population was 13,498 patients with American Joint Commission on Cancer T1 classification cervical cancer who underwent anti-cancer surgery either with hysterectomy, trachelectomy, or cervical excision and additional surgical nodal evaluation from 2004 to 2021. Temporal trends were assessed with linear segment regression model. In exploratory analysis, survival was assessed with multivariable Cox proportional hazard regression model.</div></div><div><h3>Results</h3><div>Utilization rate of sentinel lymph node biopsy with or without lymphadenectomy increased from 0.2% to 15.1% in 2004–2018 (<em>P-trend</em>&lt;0.001), followed by stabilization after 2018 (15.1% to 17.3%, <em>P-trend</em>=0.752). Utilization rate of sentinel lymph node biopsy alone without additional lymphadenectomy exceeded the rate of concurrent sentinel lymph node biopsy together with lymphadenectomy in 2018 (8.8% versus 6.3%). Following this surgery-shift in 2018, sentinel lymph node biopsy alone without additional lymphadenectomy continued to increase from 8.8% to 11.3% between 2018 and 2021 (<em>P-trend</em>&lt;0.001). In 2021, nearly two thirds of sentinel lymph node evaluation were performed by sentinel lymph node biopsy alone without additional lymphadenectomy (65.2%). Sentinel lymph node biopsy alone and sentinel lymph node biopsy with additional lymphadenectomy had comparable cervical cancer-specific survival (5-year rates 96.5% versus 95.7%, <em>P</em>=0.828) and overall survival (95.3 % versus 94.6 %, <em>P</em> =0.893).</div></div><div><h3>Conclusion</h3><div>This population-based assessment suggests that the majority of sentinel lymph node assessments for cervical cancer after the late-2010s were performed without additional lymphadenectomy.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"196 ","pages":"Pages 182-191"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825825007383","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To assess temporal trends of sentinel lymph node biopsy alone without additional lymphadenectomy at surgery for cervical cancer in the United States.

Methods

This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Study population was 13,498 patients with American Joint Commission on Cancer T1 classification cervical cancer who underwent anti-cancer surgery either with hysterectomy, trachelectomy, or cervical excision and additional surgical nodal evaluation from 2004 to 2021. Temporal trends were assessed with linear segment regression model. In exploratory analysis, survival was assessed with multivariable Cox proportional hazard regression model.

Results

Utilization rate of sentinel lymph node biopsy with or without lymphadenectomy increased from 0.2% to 15.1% in 2004–2018 (P-trend<0.001), followed by stabilization after 2018 (15.1% to 17.3%, P-trend=0.752). Utilization rate of sentinel lymph node biopsy alone without additional lymphadenectomy exceeded the rate of concurrent sentinel lymph node biopsy together with lymphadenectomy in 2018 (8.8% versus 6.3%). Following this surgery-shift in 2018, sentinel lymph node biopsy alone without additional lymphadenectomy continued to increase from 8.8% to 11.3% between 2018 and 2021 (P-trend<0.001). In 2021, nearly two thirds of sentinel lymph node evaluation were performed by sentinel lymph node biopsy alone without additional lymphadenectomy (65.2%). Sentinel lymph node biopsy alone and sentinel lymph node biopsy with additional lymphadenectomy had comparable cervical cancer-specific survival (5-year rates 96.5% versus 95.7%, P=0.828) and overall survival (95.3 % versus 94.6 %, P =0.893).

Conclusion

This population-based assessment suggests that the majority of sentinel lymph node assessments for cervical cancer after the late-2010s were performed without additional lymphadenectomy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
宫颈癌手术中前哨淋巴结活检无淋巴结切除术的时间趋势
方法这项回顾性队列研究查询了美国国家癌症研究所的监测、流行病学和最终结果计划。研究对象为美国癌症联合委员会 T1 级宫颈癌患者,共 13498 人,他们在 2004 年至 2021 年期间接受了抗癌手术,包括子宫切除术、气管切除术或宫颈切除术,并进行了额外的手术结节评估。采用线性分段回归模型评估了时间趋势。在探索性分析中,采用多变量 Cox 比例危险回归模型评估生存率。结果 2004-2018 年,前哨淋巴结活检(无论是否进行淋巴结切除术)的使用率从 0.2% 上升至 15.1%(P-trend<0.001),2018 年后趋于稳定(15.1% 至 17.3%,P-trend=0.752)。2018年,单独进行前哨淋巴结活检而不进行额外淋巴结切除术的使用率超过了同时进行前哨淋巴结活检和淋巴结切除术的使用率(8.8%对6.3%)。继 2018 年的这一手术转变之后,2018 年至 2021 年期间,单独前哨淋巴结活检而不进行额外淋巴结切除术的比例继续从 8.8% 上升至 11.3%(P-trend<0.001)。2021 年,近三分之二的前哨淋巴结评估是通过前哨淋巴结活检单独进行的,无需额外的淋巴腺切除术(65.2%)。单纯前哨淋巴结活检和前哨淋巴结活检加额外淋巴结切除术的宫颈癌特异性生存率(5 年率 96.5% 对 95.7%,P=0.828)和总生存率(95.3% 对 94.6%,P=0.893)相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
期刊最新文献
Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors. Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors – A single centre experience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1